New Variants Defeat Monoclonal Antibody Protection

The peer-review journal The Lancet Infectious Disease published the findings from an analysis that reviewed Omicron sublineage BQ.1.1 resistance to monoclonal antibodies (mAbs).

Our data revealed on November 18, 2022, indicates emerging omicron sublineages are resistant to most (i.e., BA.4.6, BA.2.75.2, and BJ.1) or all (BQ.1.1) clinically used mAbs.

Consequently, in patients at high risk, treatment with mAbs alone might not provide a therapeutic benefit in regions of the world where BQ.1.1 is spreading.

This finding suggests that additional treatment options (paxlovid) should be considered.

Furthermore, novel, broadly active mAbs are urgently needed for prophylactic or therapeutic treatment, or both, in high-risk patients.

Other news regarding U.S. FDA mAbs is posted at PrecisionVaccinations.com/Antibody.